BioSpace News Archive

Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) to discuss the Resolution ctDx Lung

Transcriptomic differences found between Luminal tumors in African American and non-Hispanic White patients suggest race-associated biology and differences in outcome in breast tumors may result from the effects of structural violence and/or genetic ancestry

Peijia Medical Limited signed a memorandum of strategic cooperation with China Resources Pharmaceutical Commercial Group Medical Devices Co., Ltd. on June 2 . Going forward, the two parties will collaborate intensively on the commercialization of TAVR products, ultimately providing more Chinese medical staff and patients with better quality goods.

Immunocore (Nasdaq: IMCR), announces the presentation of a subset analysis from the Phase 3 study exploring the overall survival benefit from tebentafusp in patients with best RECIST* response of progressive disease at the American Society of Clinical Oncology

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today summarized in a poster presentation preliminary data from the ongoing Phase 1/2 trial of CPI-0209

Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), announced that data on its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

100% (12/12) of patients with relapsed and refractory multiple myeloma treated with Arcellx’s BCMA-specific CAR-modified T-cell therapy achieved responses per IMWG criteria

Allogene Therapeutics, Inc. (Nasdaq: ALLO), today presented data from multiple studies across lead anti-CD19 AlloCAR T therapy programs in two poster presentations at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually June 4 – 8, 2021.

Y-mAbs Therapeutics, Inc. announced that Dr. Mark Souweidane, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine will present interim phase 1 dose-escalation data for omburtamab for diffuse intrinsic pontine glioma at the American Society of Clinical Oncology Virtual Annual Meeting on June 4, 2021.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab